The Institute is determined to ensure the fastest possible translation of its research activities and scientific discoveries into better outcomes for patients and the community as a whole. In doing so, SSRI recognises the importance of building and maintaining long-term professional links with the biopharmaceutical industry nationally and internationally.
Mutually beneficial network partnerships, where SSRI and the industry work towards a shared objective, generate knowledge and technological innovation for all. These partnerships also improve SSRI’s access to capital and help SSRI harness the innovation potential of their researchers, lifting their skills and intellectual knowledge base while still maintaining academic integrity. The partnerships meet industrial needs for technological progress, and also contribute to national development, ultimately improving quality of life.